Pacira Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $32.67
- Today's High:
- $33.97
- Open Price:
- $33.42
- 52W Low:
- $32.67
- 52W High:
- $58.1
- Prev. Close:
- $33.39
- Volume:
- 636013
Company Statistics
- Market Cap.:
- $1.55 billion
- Book Value:
- 17.41
- Revenue TTM:
- $669.23 million
- Operating Margin TTM:
- 11.78%
- Gross Profit TTM:
- $393.23 million
- Profit Margin:
- -0.68%
- Return on Assets TTM:
- 3.01%
- Return on Equity TTM:
- -0.58%
Company Profile
Pacira Pharmaceuticals Inc had its IPO on 2011-02-03 under the ticker symbol PCRX.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Pacira Pharmaceuticals Inc has a staff strength of 715 employees.
Stock update
Shares of Pacira Pharmaceuticals Inc opened at $33.42 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $32.67 - $33.97, and closed at $33.79.
This is a +1.2% increase from the previous day's closing price.
A total volume of 636,013 shares were traded at the close of the day’s session.
In the last one week, shares of Pacira Pharmaceuticals Inc have slipped by -4.9%.
Pacira Pharmaceuticals Inc's Key Ratios
Pacira Pharmaceuticals Inc has a market cap of $1.55 billion, indicating a price to book ratio of 2.7316 and a price to sales ratio of 2.9407.
In the last 12-months Pacira Pharmaceuticals Inc’s revenue was $669.23 million with a gross profit of $393.23 million and an EBITDA of $157.56 million. The EBITDA ratio measures Pacira Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Pacira Pharmaceuticals Inc’s operating margin was 11.78% while its return on assets stood at 3.01% with a return of equity of -0.58%.
In Q2, Pacira Pharmaceuticals Inc’s quarterly earnings growth was a positive 29.1% while revenue growth was a positive 0%.
Pacira Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 10.6496
- Trailing PE
- 0
- PEG
- -3.83
Its diluted EPS in the last 12-months stands at $-0.1 per share while it has a forward price to earnings multiple of 10.6496 and a PEG multiple of -3.83. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Pacira Pharmaceuticals Inc’s profitability.
Pacira Pharmaceuticals Inc stock is trading at a EV to sales ratio of 3.97 and a EV to EBITDA ratio of 19.2397. Its price to sales ratio in the trailing 12-months stood at 2.9407.
Pacira Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.54 billion
- Total Liabilities
- $108.91 million
- Operating Cash Flow
- $7.33 million
- Capital Expenditure
- $3.40 million
- Dividend Payout Ratio
- 0%
Pacira Pharmaceuticals Inc ended 2024 with $1.54 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.54 billion while shareholder equity stood at $807.98 million.
Pacira Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $108.91 million in other current liabilities, 46000.00 in common stock, $-142524000.00 in retained earnings and $163.24 million in goodwill. Its cash balance stood at $86.81 million and cash and short-term investments were $220.77 million. The company’s total short-term debt was $28,485,000 while long-term debt stood at $532.18 million.
Pacira Pharmaceuticals Inc’s total current assets stands at $429.32 million while long-term investments were $0.00 and short-term investments were $133.96 million. Its net receivables were $99.08 million compared to accounts payable of $24.21 million and inventory worth $92.13 million.
In 2024, Pacira Pharmaceuticals Inc's operating cash flow was $7.33 million while its capital expenditure stood at $3.40 million.
Comparatively, Pacira Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $33.79
- 52-Week High
- $58.1
- 52-Week Low
- $32.67
- Analyst Target Price
- $55.7
Pacira Pharmaceuticals Inc stock is currently trading at $33.79 per share. It touched a 52-week high of $58.1 and a 52-week low of $58.1. Analysts tracking the stock have a 12-month average target price of $55.7.
Its 50-day moving average was $36.84 and 200-day moving average was $40.02 The short ratio stood at 5.77 indicating a short percent outstanding of 0%.
Around 121.5% of the company’s stock are held by insiders while 10581.6% are held by institutions.
Frequently Asked Questions About Pacira Pharmaceuticals Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.